1. Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?

   • Daniel V. Santi
   • Gary W. Ashley
   • Francois-Clement Bidard

   Current Opinion Open access 18 January 2024 Pages: 171 - 176

   

2. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases

   • Suxiang Chen
   • Saumya Nishanga Heendeniya
   • Rakesh N. Veedu

   Leading Article Open access 22 January 2024 Pages: 177 - 203

   

3. Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies

   • Chantal T. Harris
   • Sivan Cohen

   Review Article Open access 23 January 2024 Pages: 205 - 226

   

4. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases

   • Luke M. Tomasovic
   • Kathy Liu
   • Jamie B. Spangler

   Review Article 24 November 2023 Pages: 227 - 248

   

5. Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease

   • Karen Manoutcharian
   • Goar Gevorkian

   Review Article Open access 27 January 2024 Pages: 249 - 257

6. Nano–Bio Interactions: Exploring the Biological Behavior and the Fate of Lipid-Based Gene Delivery Systems

   • Seigo Kimura
   • Hideyoshi Harashima

   Review Article 12 February 2024 Pages: 259 - 273

   

7. Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System

   • Emanuela Elisa Sorbara
   • Maria Antonietta Barbieri
   • Edoardo Spina

   Original Research Article 25 February 2024 Pages: 275 - 285

   

8. Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study

   • Ching-Liang Ho
   • Tsu-Yi Chao
   • Hsuan-Yu Lin

   Original Research Article 09 January 2024 Pages: 287 - 299

   

9. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study

   • Gyeongseon Shin
   • Byung Soo Kim
   • SeungJin Bae

   Original Research Article Open access 12 January 2024 Pages: 301 - 311

   

10. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

    • Xiaojiao Li
    • Bing Li
    • Yanhua Ding

    Original Research Article 27 December 2023 Pages: 313 - 321

    

11. Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries

    • Hyunjung Woo
    • Gyeongseon Shin
    • SeungJin Bae

    Correction Open access 22 January 2024 Pages: 323 - 323